Translational research in stroke: Taking advances in the pathophysiology and treatment of stroke from the experimental setting to clinical trials

Current Neurology and Neuroscience Reports

Volumn 7, Issue 1, 2007, Pages 35-41

  Fisher, Marc ^a   Henninger, Nils ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; DISUFENTON SODIUM; NEUROPROTECTIVE AGENT; NYX 059; PLACEBO; UNCLASSIFIED DRUG;

BRAIN ISCHEMIA; CEREBROVASCULAR DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; EXPERIMENTAL DESIGN; GENE EXPRESSION; HIBERNATION; HUMAN; ISCHEMIC PRECONDITIONING; MEDICAL RESEARCH; NEUROIMAGING; NONHUMAN; PATHOPHYSIOLOGY; PATIENT SAFETY; POSITRON EMISSION TOMOGRAPHY; REVIEW; RNA TRANSLATION; STROKE; THERAPY EFFECT;

ANIMALS; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; HUMANS; RESEARCH;

EID: 33846692415     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-007-0019-1     Document Type: Review

References (60)

1. Hossmann KA: Pathophysiology and therapy of experimental stroke. Cell Mol Neurobiol 2006, In press.
2. Lo EH, Dalkara T, Moskowitz MA: Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 2003, 4:399-415.
3. Cheng YD, Al-Khoury L, Zivin JA: Neuroprotection for ischemic stroke: two decades of success and failure. NeuroRx 2004, 1:36-45.
4. Birmingham K: What is translational research? Nat Med 2002, 8:647.
5. Labiche LA, Grotta JC: Clinical trials for cytoprotection in stroke. NeuroRx 2004, 1:46-70.
6. Lees KR, Zivin JA, Ashwood T, et al.: NXY-059 for acute ischemic stroke. N Engl J Med 2006, 354:588-600.
7. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995, 333:1581-1587.
8. Smith WS, Sung G, Starkman S, et al.: Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke 2005, 36:1432-1438.
9. Khatri P, Neff J, Broderick JP, et al.: Revascularization end points in stroke interventional trials: recanalization versus reperfusion in IMS-I. Stroke 2005, 36:2400-2403.
10. Ringelstein EB, Biniek R, Weiller C, et al.: Type and extent of hemispheric brain infarctions and clinical outcome in early and delayed middle cerebral artery recanalization. Neurology 1992, 42:289-298.
11. Fisher M: Characterizing the target of acute stroke therapy. Stroke 1997, 28:866-872.
12. Fisher M: The ischemic penumbra: identification, evolution and treatment concepts. Cerebrovasc Dis 2004, 17(Suppl 1):1-6.
13. Ginsberg MD: Adventures in the pathophysiology of brain ischemia: penumbra, gene expression, neuroprotection: the 2002 Thomas Willis Lecture. Stroke 2003, 34:214-223.
14. Chong ZZ, Li F, Maiese K: Oxidative stress in the brain: novel cellular targets that govern survival during neuro-degenerative disease. Prog Neurobiol 2005, 75:207-246.
15. Fisher M, Ratan R: New perspectives on developing acute stroke therapy. Ann Neurol 2003, 53:10-20.
16. Stagliano NE, Perez-Pinzon MA, Moskowitz MA, Huang PL: Focal ischemic preconditioning induces rapid tolerance to middle cerebral artery occlusion in mice. J Cereb Blood Flow Metab 1999, 19:757-761.
17. Kirino T: Ischemic tolerance. J Cereb Blood Flow Metab 2002, 22:1283-1296.
18. Drew KL, Rice ME, Kuhn TB, Smith MA: Neuroprotective adaptations in hibernation: therapeutic implications for ischemia-reperfusion, traumatic brain injury and neuro-degenerative diseases. Free Radic Biol Med 2001, 31:563-573.
19. Sharp FR, Lu A, Tang Y, Millhorn DE: Multiple molecular penumbras after focal cerebral ischemia. J Cereb Blood Flow Metab 2000, 20:1011-1032.
20. Lipton P: Ischemic cell death in brain neurons. Physiol Rev 1999, 79:1431-1568.
21. Traystman RJ: Animal models of focal and global cerebral ischemia. ILAR J 2003, 44:85-95.
22. Fukuda S, del Zoppo GJ: Models of focal cerebral ischemia in the nonhuman primate. ILAR J 2003, 44:96-104.
23. Hossmann KA: Experimental models for the investigation of brain ischemia. Cardiovasc Res 1998, 39:106-120.
24. Henninger N, Sicard KM, Bouley J, et al.: The proteasome inhibitor VELCADE reduces infarction in rat models of focal cerebral ischemia. Neurosci Lett 2006, 398:300-305.
25. Kollmar R, Henninger N, Bardutzky J, et al.: Combination therapy of moderate hypothermia and thrombolysis in experimental thromboembolic stroke - an MRI study. Exp Neurol 2004, 190:204-212.
26. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999, 30:2752-2758.
27. O'Collins VE, Macleod MR, Donnan GA, et al.: 1,026 experimental treatments in acute stroke. Ann Neurol 2006, 59:467-477.
28. Dirnagl U: Bench to bedside: the quest for quality in experimental stroke research. J Cereb Blood Flow Metab 2006, In press.
29. Macleod MR, O'Collins T, Howells DW, Donnan GA: Pooling of animal experimental data reveals influence of study design and publication bias. Stroke 2004, 35:1203-1238.
30. Astrup J, Siesjo BK, Symon L: Thresholds in cerebral ischemia - the ischemic penumbra. Stroke 1981, 12:723-725.
31. Hakim AM: The cerebral ischemic penumbra. Can J Neurol Sci 1987, 14:557-559.
32. Castellanos M, Sobrino T, Castillo J: Evolving paradigms for neuroprotection: molecular identification of ischemic penumbra. Cerebrovasc Dis 2006, 21(Suppl 2):71-79.
33. Dirnagl U, Iadecola C, Moskowitz MA: Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 1999, 22:391-397.
34. Baron JC: Mapping the ischaemic penumbra with PET: implications for acute stroke treatment. Cerebrovasc Dis 1999, 9:193-201.
35. Heiss WD, Graf R, Lottgen J, et al.: Repeat positron emission tomographic studies in transient middle cerebral artery occlusion in cats: residual perfusion and efficacy of postischemic reperfusion. J Cereb Blood Flow Metab 1997, 17:388-400.
36. Marchal G, Beaudouin V, Rioux P, et al.: Prolonged persistence of substantial volumes of potentially viable brain tissue after stroke: a correlative PET-CT study with voxel-based data analysis. Stroke 1996, 27:599-606.
37. Furlan M, Marchal G, Viader F, et al.: Spontaneous neurological recovery after stroke and the fate of the ischemic penumbra. Ann Neurol 1996, 40:216-226.
38. Saita K, Chen M, Spratt NJ, et al.: Imaging the ischemic penumbra with 18F-fluoromisonidazole in a rat model of ischemic stroke. Stroke 2004, 35:975-980.
39. Read SJ, Hirano T, Abbott DF, et al.: The fate of hypoxic tissue on 18F-fluoromisonidazole positron emission tomography after ischemic stroke. Ann Neurol 2000, 48:228-235.
40. Sa de Camargo EC, Koroshetz WJ: Neuroimaging of ischemia and infarction. NeuroRx 2005, 2:265-276.
41. Weber R, Ramos-Cabrer P, Hoehn M: Present status of magnetic resonance imaging and spectroscopy in animal stroke models. J Cereb Blood Flow Metab 2006, 26:591-604.
42. Schlaug G, Benfield A, Baird AE, et al.: The ischemic penumbra: operationally defined by diffusion and perfusion MRI. Neurology 1999,53:1528-1537.
43. Kidwell CS, Alger JR, Saver JL: Beyond mismatch: evolving paradigms in imaging the ischemic penumbra with multimodal magnetic resonance imaging. Stroke 2003, 34:2729-2735.
44. Shen Q, Fisher M, Sotak CH, Duong TQ: Effects of reperfusion on ADC and CBF pixel-by-pixel dynamics in stroke: characterizing tissue fates using quantitative diffusion and perfusion imaging. J Cereb Blood Flow Metab 2004, 24:280-290.
45. Wu O, Koroshetz WJ, Ostergaard L, et al.: Predicting tissue outcome in acute human cerebral ischemia using combined diffusion- and perfusion-weighted MR imaging. Stroke 2001, 32:933-942.
46. Furlan AJ, Eyding D, Albers GW, et al.: Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006, 37:1227-1231.
47. Hacke W, Albers G, Al-Rawi Y, et al.: The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005, 36:66-73.
48. Albers GW, Thiijs VN, Wechsler L, et al.: Results of the Diffusion-weighted imaging evaluation for understanding stroke evolution (DEFUSE) study [abstract]. Stroke 2006, 37:635.
49. Ribo M, Molina CA, Rovira A, et al.: Safety and efficacy of intravenous tissue plasminogen activator stroke treatment in the 3- to 6-hour window using multimodal transcranial Doppler/MRI selection protocol. Stroke 2005, 36:602-606.
50. Thomalla G, Schwark C, Sobesky J, et al.: Outcome and symptomatic bleeding complications of intravenous thrombolysis within 6 hours in MRI-selected stroke patients: comparison of a German multicenter study with the pooled data of ATLANTIS, ECASS, and NINDS tPA trials. Stroke 2006, 37:852-858.
51. Wintermark M, Maeder P, Thiran JP, et al.: Quantitative assessment of regional cerebral blood flows by perfusion CT studies at low injection rates: a critical review of the underlying theoretical models. Eur Radiol 2001, 11:1220-1230.
52. Wintermark M, Reichhart M, Thiran JP, et al.: Prognostic accuracy of cerebral blood flow measurement by perfusion computed tomography, at the time of emergency room admission, in acute stroke patients. Ann Neurol 2002, 51:417-432.
53. Wintermark M, Flanders AE, Velthuis B, et al.: Perfusion-CT assessment of infarct core and penumbra: receiver operating characteristic curve analysis in 130 patients suspected of acute hemispheric stroke. Stroke 2006, 37:979-985.
54. Murphy BD, Fox AJ, Lee DH, et al.: Identification of penumbra and infarct in acute ischemic stroke using computed tomography perfusion-derived blood flow and blood volume measurements. Stroke 2006, 37:1771-1777.
55. Recommendations for clinical trial evaluation of acute stroke therapies. Stroke 2001, 32:1598-1606.
56. Gladstone DJ, Black SE, Hakim AM: Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 2002, 33:2123-2336.
57. Sugawara T, Fujimura M, Noshita N, et al.: Neuronal death/survival signaling pathways in cerebral ischemia. NeuroRx 2004, 1:17-25.
58. Marshall JW, Duffin KJ, Green AR, Ridley RM: NXY-059, a free radical-trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Stroke 2001, 32:190-198.
59. Marshall JW, Cummings RM, Bowes LJ, et al.: Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 hours after occlusion. Stroke 2003, 34:2228-2233.
60. Lees KR, Barer D, Ford GA, et al.: Tolerability of NXY-059 at higher target concentrations in patients with acute stroke. Stroke 2003, 34:482-487.